Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Grapheal raises EUR1.9 million to advance development of embedded biosensing technology and application in digital COVID testing and wound monitoring: Includes seed financing from Novalis Biotech and private investors, support from Bpifrance as well as non-dilutive grants

Abstract:
Grapheal, a developer of graphene-based embedded biosensors for on-site diagnostics and remote patient monitoring, announced today that it has raised a total of EUR1.9 million in equity and non-dilutive sources, including seed financing from Novalis Biotech’s Acceleration Fund, several innovation grants, and Bpifrance convertible notes and loans.

Grapheal raises EUR1.9 million to advance development of embedded biosensing technology and application in digital COVID testing and wound monitoring: Includes seed financing from Novalis Biotech and private investors, support from Bpifrance as well as non-dilutive grants

Grenoble, France | Posted on February 10th, 2021

The funds will be used to advance the industrialization of Grapheal’s flexible graphene-based biosensor technology. This sensing technology combines novel electronic nanomaterials, embedded wireless electronics, software data analysis, and medical cloud IoT technologies. The first two applications of the technology will be a new generation digital COVID-19 test (TestNPass) for rapid screening in high-traffic areas, such as airports, and a wound care digital assistant (WoundLAB) to improve the monitoring of hard-to-heal wounds. The funds will also be used to validate the two devices in the field and complete clinical studies, respectively.

“Grapheal merges digital bioelectronic sensing technologies with connectivity into embedded systems for on-site diagnostics and remote patient monitoring, so is a perfect fit to the Novalis portfolio” said Wim Van Criekinge, co-founder of Novalis Biotech, who has also been appointed to the Grapheal Board of Directors. “There is enormous potential for applications of their digital technology in the medical field, but the rapid COVID-19 saliva test could be the game-changing test the world needs to safely return to normal, particularly at airports, concert halls, and stadiums. Their technology is delivering a tamper-proof sanitary pass that is confidential and compliant with stringent data privacy regulations, such as European GDPR. This is definitely a critical asset for their differentiation with competing products.”

TestNPass is Grapheal’s diagnostic test based on saliva sampling that can be used to rapidly screen for the COVID-19 infection. Within 5 minutes, the digital test detects the presence of the virus without the requirement of dedicated reading equipment other than a smartphone or a standard NFC-connected device. When the SARS-CoV-2 virus binds to antibodies contained in TestNPass, a specific electrical signal is detected. This signal can be captured electronically on the device, which speeds up the diagnosis and allows the result's secure digital transfer.

WoundLAB is a flexible and transparent graphene-based biosensor patch that continuously records and stores wound biochemical parameters. A smartphone app is then used to communicate this data to a telemedicine cloud for data aggregation and further analysis. This allows caregivers to monitor wound healing in their patients remotely, with prompt alerts if any infections or medical complications arise.

“We are very thankful to everyone that participated in our funding, from the seed capital provided by Novalis Biotech, each grant approval, and the Grenoble and La French Tech teams at Bpifrance for their continuous support,” said Dr. Vincent Bouchiat, CEO of Grapheal. “The medical applications of graphene are only just beginning to be explored, and we are leading those endeavors. With this funding in place, we believe our first product could be on the market before the end of 2021.”

####

About Grapheal
Grapheal develops wearable and disposable sensors based on graphene that enables continuous monitoring and diagnosis. These flexible biosensors empower caregivers with an improved and individualized assessment tool for precision medicine. The company is among the first in Europe to focus on healthcare applications of graphene. Grapheal is a spin-off from the Neel Institute at the French National Centre for Scientific Research (CNRS). CNRS, together with Grenoble University (UGA) licensed key patents to Grapheal, which was incubated and supported by Grenoble’s technology transfer office SATT Linksium. Since its creation in 2019, Grapheal received numerous innovation awards, including the French i-Lab and i-Nov prizes, EDF Pulse prize, EU-funded EIT Health Headstart award, and was integrated into several acceleration entrepreneurship programs worldwide (HEC Challenge+, Creative Destruction Lab, MassChallenge, and NETVA). Grapheal is also an associate member of the Graphene Flagship, a EUR 1 billion, 10-year collaborative program supported by the European Union. Grapheal is based on the former works in nanoelectronics and material science performed by the CNRS team lead by Dr. Vincent Bouchiat, combined with the engineering expertise in digital connectivity of Behnaz Djoharian. Both are co-founders of the company. For more information, please visit www.grapheal.com.

About Novalis Biotech
Novalis Biotech (Ghent, Belgium) is an early stage venture capital investor in technologies that revolutionize healthcare. The company’s core competence lies in digitalization in the life sciences with a focus on bioinformatics, genomics and diagnostics. Novalis strongly believes in applying innovative enabling technology to advance the prevention, diagnosis, or treatment of a disease. Novalis Biotech Acceleration (Fund II) announced the first closing in November 2020.
For more information, please visit www.noval.is.

For more information, please click here

Contacts:
Grapheal Novalis Halsin Partners (media)
Dr. Vincent Bouchiat Jan Van den Berghe Mike Sinclair
+33 456387074 +44 20 7318 2955

Copyright © Grapheal

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Stability of perovskite solar cells reaches next milestone January 27th, 2023

Qubits on strong stimulants: Researchers find ways to improve the storage time of quantum information in a spin rich material January 27th, 2023

UCF researcher receives Samsung International Global Research Outreach Award: The award from the multinational electronics corporation will fund the development of infrared night vision and thermal sensing camera technology for cell phones and consumer electronics January 27th, 2023

Temperature-sensing building material changes color to save energy January 27th, 2023

Graphene/ Graphite

Trial by wind: Testing the heat resistance of carbon fiber-reinforced ultra-high-temperature ceramic matrix composites: Researchers use an arc-wind tunnel to test the heat resistance of carbon fiber reinforced ultra-high-temperature ceramic matrix composites November 18th, 2022

Rice turns asphaltene into graphene for composites: ‘Flashed’ byproduct of crude oil could bolster materials, polymer inks November 18th, 2022

New study introduces the best graphite films: The work by Distinguished Professor Feng Ding at UNIST has been published in the October 2022 issue of Nature Nanotechnology November 4th, 2022

Current and Future Developments in Nanomaterials and Carbon Nanotubes: Applications of Nanomaterials in Energy Storage and Electronics October 28th, 2022

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Possible Futures

One of the causes of aggressive liver cancer discovered: a 'molecular staple' that helps repair broken: DNA Researchers describe a new DNA repair mechanism that hinders cancer treatment January 27th, 2023

Stability of perovskite solar cells reaches next milestone January 27th, 2023

Danish quantum physicists make nanoscopic advance of colossal significance January 27th, 2023

UC Irvine researchers decipher atomic-scale imperfections in lithium-ion batteries: Team used super high-resolution microscopy enhanced by deep machine learning January 27th, 2023

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Nanomedicine

One of the causes of aggressive liver cancer discovered: a 'molecular staple' that helps repair broken: DNA Researchers describe a new DNA repair mechanism that hinders cancer treatment January 27th, 2023

New nanoparticles deliver therapy brain-wide, edit Alzheimer’s gene in mice: UW researchers have found a way to move gene therapies through the blood-brain barrier, a crucial step for brain-wide CRISPR treatments of disorders like Alzheimer's and Parkinson's disease January 20th, 2023

Team undertakes study of two-dimensional transition metal chalcogenides Important biomedical application, including biosensing December 9th, 2022

SLAC/Stanford researchers discover how a nano-chamber in the cell directs protein folding: The results challenge a 70-year-old theory of how proteins fold in our cells and have profound implications for treating diseases linked to protein misfolding December 9th, 2022

Announcements

UCF researcher receives Samsung International Global Research Outreach Award: The award from the multinational electronics corporation will fund the development of infrared night vision and thermal sensing camera technology for cell phones and consumer electronics January 27th, 2023

Temperature-sensing building material changes color to save energy January 27th, 2023

Quantum sensors see Weyl photocurrents flow: Boston College-led team develops new quantum sensor technique to image and understand the origin of photocurrent flow in Weyl semimetals January 27th, 2023

Department of Energy announces $9.1 million for research on quantum information science and nuclear physics: Projects span the development of quantum computing, algorithms, simulators, superconducting qubits, and quantum sensors for advancing nuclear physics January 27th, 2023

Nanobiotechnology

One of the causes of aggressive liver cancer discovered: a 'molecular staple' that helps repair broken: DNA Researchers describe a new DNA repair mechanism that hinders cancer treatment January 27th, 2023

New nanoparticles deliver therapy brain-wide, edit Alzheimer’s gene in mice: UW researchers have found a way to move gene therapies through the blood-brain barrier, a crucial step for brain-wide CRISPR treatments of disorders like Alzheimer's and Parkinson's disease January 20th, 2023

Team undertakes study of two-dimensional transition metal chalcogenides Important biomedical application, including biosensing December 9th, 2022

SLAC/Stanford researchers discover how a nano-chamber in the cell directs protein folding: The results challenge a 70-year-old theory of how proteins fold in our cells and have profound implications for treating diseases linked to protein misfolding December 9th, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project